|
1
|
Sathornsumetee S, Reardon DA, Desjardins
A, et al: Molecularly targeted therapy for malignant glioma.
Cancer. 110:13–24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang Y and Jiang T: Understanding high
grade glioma: Molecular mechanism, therapy and comprehensive
management. Cancer Lett. 331:139–146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saini KS, Loi S, de Azambuja E, et al:
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the
treatment of breast cancer. Cancer Treat Rev. 39:935–946. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Redman EK, Brookes PS and Karcz MK: Role
of p90(RSK) in regulating the crabtree effect: implications for
cancer. Biochem Soc Trans. 41:124–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hasskarl J: Sorafenib: Targeting multiple
tyrosine kinases in cancer. Recent Results Cancer Res. 201:145–164.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han L, Yang Y, Yue X, et al: Inactivation
of PI3K/AKT signaling inhibits glioma cell growth through
modulation of beta-catenin-mediated transcription. Brain Res.
1366:9–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chin YR and Toker A: Function of Akt/PKB
signaling to cell motility, invasion and the tumor stroma in
cancer. Cell Signal. 21:470–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghayad SE and Cohen PA: Inhibitors of the
PI3K/Akt/mTOR pathway: New hope for breast cancer patients. Recent
Pat Anticancer Drug Discov. 5:29–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Q, Wu J, Zheng H, et al: Discovery of
3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as
a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling
pathways. Bioorg Med Chem Lett. 20:4526–4530. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Steelman LS, Abrams SL, Whelan J, et al:
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT
pathways to leukemia. Leukemia. 22:686–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McCubrey JA, Steelman LS, Kempf CR, et al:
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol.
226:2762–2781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee J, Zhang G, Wu X, Xu F, Zhou J and
Zhang X: Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+
chronic myeloid leukemia K562 cells involve, AKT, ERK and NF-kappaB
modulation. J Cancer Res Clin Oncol. 138:2095–2102. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang XM, Zhang L, Ding GF and Wang QZ:
Inhibitory effect of dihydroartemisinin on the growth of human
prostate cancer PC-3 M cells and its mechanism. Zhonghua Nan Ke
Xue. 18:590–594. 2012.(In Chinese). PubMed/NCBI
|
|
16
|
Feng X, Li L, Jiang H, Jiang K, Jin Y and
Zheng J: Dihydroartemisinin potentiates the anticancer effect of
cisplatin via mTOR inhibition in cisplatin-resistant ovarian cancer
cells: involvement of apoptosis and autophagy. Biochem Biophys Res
Commun. 444:376–381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu M, Sun L, Zhou J and Yang J:
Dihydroartemisinin induces apoptosis in colorectal cancer cells
through the mitochondria-dependent pathway. Tumour Bio.
35:5307–5314. 2014. View Article : Google Scholar
|
|
18
|
Hoeflich KP, O'Brien C, Boyd Z, et al: In
vivo antitumor activity of MEK and phosphatidylinositol 3-kinase
inhibitors in basal-like breast cancer models. Clin Cancer Res.
15:4649–4664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kubiatowski T, Jang T, Lachyankar MB,
Salmonsen R, Nabi RR, Quesenberry PJ, Litofsky NS, Ross AH and
Recht LD: Association of increased phosphatidylinositol 3-kinase
signaling with increased invasiveness and gelatinase activity in
malignant gliomas. J Neurosurg. 95:480–488. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mirzoeva OK, Das D, Heiser LM, et al:
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase
feedback signaling determine susceptibility of breast cancer cells
to MEK inhibition. Cancer Res. 69:565–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sheppard KE, Cullinane C, Hannan KM, et
al: Synergistic inhibition of ovarian cancer cell growth by
combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J
Cancer. 49:3936–3944. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang XJ, Li CT, Zhang WP, Lu YB, Fang SH
and Wei EQ: Dihydroartemisinin potentiates the cytotoxic effect of
temozolomide in rat C6 glioma cells. Pharmacology. 82:1–9. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu YY, Chen TS, Qu JL, Pan WL, Sun L and
Wei XB: Dihydroartemisinin (DHA) induces caspase-3-dependent
apoptosis in human lung adenocarcinoma ASTC-a-1 cells. J Biomed
Sci. 16:162009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Wang W, Xu J, et al:
Dihydroartemisinin inhibits tumor growth of human osteosarcoma
cells by suppressing Wnt/beta-catenin signaling. Oncol Rep.
30:1723–1730. 2013.PubMed/NCBI
|
|
26
|
Heath-Engel HM, Chang NC and Shore GC: The
endoplasmic reticulum in apoptosis and autophagy: Role of the BCL-2
protein family. Oncogene. 27:6419–6433. 2008. View Article : Google Scholar : PubMed/NCBI
|
